je.st
news
Tag: cancer
AbbVie boosts cancer drug pipeline with $21 billion Pharmacyclics deal
2015-03-05 13:11:44| Biotech - Topix.net
AbbVie Inc is to buy Pharmacyclics Inc for about $21 billion, giving it access to what is expected to be one of the world's top-selling cancer drugs and expanding its reach in the profitable oncology field. The deal -- the latest example of a big drugmaker swooping on a biotech firm to refill its medicine pipeline -- confounds expectations that Pharmacyclics would sell out to Johnson & Johnson .
Tags: deal
drug
cancer
billion
J&J nearing deal to buy cancer drug maker Pharmacyclics: FT
2015-03-05 03:32:16| Food - Topix.net
Johnson & Johnson is close to buying cancer drug maker Pharmacyclics Inc in the coming days, the Financial Times reported, citing sources. A bid from J&J is expected to value Pharmacyclics near its $17.5 billion market value or at a premium, FT said on Wednesday, citing people familiar with the matter.
Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer
2015-03-05 00:30:00| Merck.com - Product News
Dateline City: TOKYO & KENILWORTH, N.J. Combination clinical studies of lenvatinib, eribulin and pembrolizumab to be explored TOKYO & KENILWORTH, N.J.--(BUSINESS WIRE)--Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, through a subsidiary, announced today a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Mercks anti-PD-1 therapy, pembrolizumab (marketed in the U.S. under the brand name KEYTRUDA), in combination with Eisai oncology compounds lenvatinib mesylate (a multi-targeting RTK inhibitor marketed in the U.S. Language: English Contact: Eisai Public Relations Department+81-(0)3-3817-5120orEisai Investor Relations+81-(0)3-3817-5327orMerck Media RelationsPamela Eisele, 267-305-3558or Claire Mulhearn, 908-236-1118orMerck Investor RelationsJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
FDA approves Bristol-Myers drug for lung cancer
2015-03-04 21:48:13| Biotech - Topix.net
The Food and Drug Administration on Wednesday expanded approval of an innovative Bristol-Myers Squibb drug to treat the most common form of lung cancer. Regulators cleared Opdivo for patients with advanced squamous non-small cell lung cancer, which accounts for seven out of eight lung cancer patients.
Graphene shown to neutralize cancer stem cells
2015-02-27 19:13:29| Extremetech
Elite materials like graphene usually aren’t just lone success stories. Generally, the whole family of related materials — oxides, nitrides, or other derivatives — are all sought after for unique applications. As it typically happens, folks first imagine using a promising new material to store bits or energy, but then settle for trying to make…
Sites : [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] next »